Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

Financial Burden of Multiple Sclerosis Hospitalizations; A National Study during 2009-2019 in the United States.

Phase 1 Safety and Pharmacodynamic Results of VRDN-001, a Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R) in Development for Thyroid Eye Disease (TED)